Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 10, 2023
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
David Amsellem Maintained (XERS) at Buy with Decreased Target to $4 on, Nov 10th, 2023
David Amsellem of Piper Sandler, Maintained "Xeris Biopharma Holdings, Inc." (XERS) at Buy with Decreased Target from $5 to $4 on, Nov 10th, 2023.
David has made no other calls on XERS in the last 4 months.
There are 2 other peers that have a rating on XERS. Out of the 2 peers that are also analyzing XERS, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Robin Garner of "Craig-Hallum" Initiated at Strong Buy and Held Target at $4.5 on, Monday, August 28th, 2023
- Oren Livnat of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $6 on, Wednesday, August 9th, 2023
